Filing summary
Business context and period: Scinai Immunotherapeutics Ltd., a foreign private issuer, furnished this Form 6-K for October 2026. The filing reports that on October 13, 2026, the company issued a press release titled “Scinai Expands CDMO Business with $5.1 Million Development and Clinical Manufacturing Agreement.” The press release is identified as Exhibit 99.1, but its text is not included in the supplied filing content.
Financial and operating information
The filing identifies a $5.1 million development and clinical manufacturing agreement. It does not provide a clear value for the contract’s payment schedule, revenue recognition, costs, margins, duration, or expected cash-flow impact. No results for revenue, profit, cash flow, debt, or liquidity are provided.
Changes, outlook, and risks
The agreement represents a reported expansion of Scinai’s CDMO business. The supplied text contains no prior-period comparison, guidance, detailed management commentary, risk discussion, contingencies, or other unusual items.
Important facts to verify
- Review Exhibit 99.1 for the agreement’s scope, customer, term, milestones, and payment conditions.
- Verify when and how the $5.1 million is expected to be recognized as revenue and what costs are associated with performance.
- Assess the agreement’s expected effect on cash flow, margins, and the company’s broader CDMO business.
The 6-K states that it is incorporated by reference into specified Form S-8 and Form F-3 registration statements.